{"entity":{"id":"nct06281678","kind":"trial","name":"A Study of IBI363 in Subjects with Advanced Solid Malignancies","aka":[],"tldr":"A phase 2 trial of IBI363 in melanoma and non-small-cell lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","summary":"A Study of IBI363 in Subjects with Advanced Solid Malignancies is a phase 2 interventional study registered as NCT06281678 by Innovent Biologics (Suzhou) Co. Ltd., with 178 participants planned, started 2024-04-08 and due to reach its primary completion in 2026-03-01. Interventions recorded: IBI363. Conditions listed: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06281678","url":"https://clinicaltrials.gov/study/NCT06281678"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","nsclc","sclc","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["ibi363"],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06281678","phase":"2","setting":"A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","enrolled":178,"outcomes":[]},"route":"/trials/nct06281678/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"ibi363","kind":"drug","name":"IBI363","route":"/drugs/ibi363/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}]}}